Tags

Type your tag names separated by a space and hit enter

From endocannabinoid profiling to 'endocannabinoid therapeutics'.

Abstract

The discovery of the endocannabinoid signalling system, that is, of cannabinoid receptors, their endogenous ligands, known as endocannabinoids, and of endocannabinoid anabolic and catabolic enzymes, raised several questions regarding the physiopathological role of these mediators. Several of these questions were answered by investigating alterations in the levels of the most studied endocannabinoids, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), in tissues of animal models of disorders, and in bioptic samples and biological fluids (cerebrospinal fluid and blood) of human volunteers. Subsequently, the pharmacological effects of synthetic compounds that selectively target the cannabinoid CB(1) and CB(2) receptors, and endocannabinoid anabolic and catabolic enzymes, established cause-effect relationships between pathological alterations in endocannabinoid levels and the symptoms and progress of several disorders, including emesis, obesity, metabolic disorders, hepatic diseases, pain, inflammation and neurological and neuropsychiatric disorders. These new developments are discussed in this second review on the endocannabinoids, together with the results of pre-clinical and clinical studies on the potential therapeutic use of plant-derived cannabinoids and synthetic agents that manipulate pharmacologically the action at cannabinoid receptors or the tissue levels of AEA and 2-AG.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Via Campi Flegrei 34, 80078 Pozzuoli, Naples, Italy.

    ,

    Source

    Current opinion in chemical biology 13:3 2009 Jun pg 321-31

    MeSH

    Animals
    Cannabinoid Receptor Agonists
    Cannabinoid Receptor Antagonists
    Cannabinoid Receptor Modulators
    Endocannabinoids
    Feeding and Eating Disorders
    Humans
    Inflammation
    Mental Disorders
    Neurodegenerative Diseases
    Pain
    Receptors, Cannabinoid

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    19497779

    Citation

    Ligresti, Alessia, et al. "From Endocannabinoid Profiling to 'endocannabinoid Therapeutics'." Current Opinion in Chemical Biology, vol. 13, no. 3, 2009, pp. 321-31.
    Ligresti A, Petrosino S, Di Marzo V. From endocannabinoid profiling to 'endocannabinoid therapeutics'. Curr Opin Chem Biol. 2009;13(3):321-31.
    Ligresti, A., Petrosino, S., & Di Marzo, V. (2009). From endocannabinoid profiling to 'endocannabinoid therapeutics'. Current Opinion in Chemical Biology, 13(3), pp. 321-31. doi:10.1016/j.cbpa.2009.04.615.
    Ligresti A, Petrosino S, Di Marzo V. From Endocannabinoid Profiling to 'endocannabinoid Therapeutics'. Curr Opin Chem Biol. 2009;13(3):321-31. PubMed PMID: 19497779.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - From endocannabinoid profiling to 'endocannabinoid therapeutics'. AU - Ligresti,Alessia, AU - Petrosino,Stefania, AU - Di Marzo,Vincenzo, Y1 - 2009/06/03/ PY - 2009/03/17/received PY - 2009/04/17/accepted PY - 2009/6/6/entrez PY - 2009/6/6/pubmed PY - 2009/10/1/medline SP - 321 EP - 31 JF - Current opinion in chemical biology JO - Curr Opin Chem Biol VL - 13 IS - 3 N2 - The discovery of the endocannabinoid signalling system, that is, of cannabinoid receptors, their endogenous ligands, known as endocannabinoids, and of endocannabinoid anabolic and catabolic enzymes, raised several questions regarding the physiopathological role of these mediators. Several of these questions were answered by investigating alterations in the levels of the most studied endocannabinoids, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), in tissues of animal models of disorders, and in bioptic samples and biological fluids (cerebrospinal fluid and blood) of human volunteers. Subsequently, the pharmacological effects of synthetic compounds that selectively target the cannabinoid CB(1) and CB(2) receptors, and endocannabinoid anabolic and catabolic enzymes, established cause-effect relationships between pathological alterations in endocannabinoid levels and the symptoms and progress of several disorders, including emesis, obesity, metabolic disorders, hepatic diseases, pain, inflammation and neurological and neuropsychiatric disorders. These new developments are discussed in this second review on the endocannabinoids, together with the results of pre-clinical and clinical studies on the potential therapeutic use of plant-derived cannabinoids and synthetic agents that manipulate pharmacologically the action at cannabinoid receptors or the tissue levels of AEA and 2-AG. SN - 1879-0402 UR - https://www.unboundmedicine.com/medline/citation/19497779/From_endocannabinoid_profiling_to_'endocannabinoid_therapeutics'_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1367-5931(09)00060-X DB - PRIME DP - Unbound Medicine ER -